Ana Martin-Suarez

Ana Martin-Suarez

Auto-generated profile, based on publicly available information

Ana Martin-Suarez

Departamento de Ciencias Farmacéuticas, Universidad de Salamanca, Salamanca, Spain

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2010 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
NRNatalia Revilla
Natalia Revilla
AMAna Martín‐Suárez
Ana Martín‐Suárez
MPMarta Paz Pérez
Marta Paz Pérez
FGFélix Martín González
Félix Martín González
MGMaría del Mar Fernández de Gatta
María del Mar Fernández de Gatta
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Despite the frequent use of vancomycin in intensive care unit (ICU) patients, few studies aimed at characterizing vancomycin population pharmacokinetics have been performed in this critical population.• Population pharmacokinetics coupled with pharmacodynamic analysis, in order to optimize drug exposure and hence antibacterial effectiveness, has been little applied in these specific patients. WHAT THIS STUDY ADDS • Our population model characterized the pharmacokinetic profile of vancomycin in adult ICU patients, higher distribution volume values (V) being observed when the patient's serum creatinine (CrSe) was greater than 1 mg dl−1.• Age and creatinine clearance (CLcr) were identified as the main covariates explaining the pharmacokinetic variability in vancomycin CL.• Our pharmacokinetic/pharmacodynamic (PK/PD) simulation should aid clinicians to select initial vancomycin doses that will maximize the rate of response in the ICU setting, taking into account the patient's age and renal function as well as the susceptibility of Staphylococcus aureus.AIM: To estimate the vancomycin pharmacokinetic profile in adult ICU patients and to assess vancomycin dosages for increasing the likelihood of optimal exposure.METHODS: Five hundred and sixty‐nine concentration–time data from 191 patients were analysed using a population pharmacokinetic approach (NONMEN™). External model evaluation was made in 46 additional patients. The 24 h area under the concentration–time curve (AUC(0,24 h)) was derived from the final model. Minimum inhibitory concentration (MIC) values for S. aureus were obtained from the EUCAST database. AUC(0,24 h) : MIC ≥ 400 was considered as PK/PD efficacy index. The probability of different dosages attaining the target considering different strains of S. aureus and patient subgroups was estimated with Monte Carlo simulation.RESULTS: Vancomycin CL showed a significant dependence on patient age and renal function whereas CrSe > 1 mg dl−1 increased V more than twofold. For our representative ICU patient, 61 years, 73 kg, CrSe= 1.4 mg dl−1, measured CLCr= 74.7 ml min−1, the estimated values were CL = 1.06 ml min−1 kg−1 and V= 2.04 l kg−1. The cumulative fraction of response for a standard vancomycin dose (2 g day−1) was less than 25% for VISA strains, and 33% to 95% for susceptible S. aureus, depending on patient characteristics.CONCLUSIONS: Simulations provide useful information regarding the initial assessment of vancomycin dosing, the conventional dosing regimen probably being suboptimal in adult ICU patients. A graphic approach provides the recommended dose for any selected probability of attaining the PK/PD efficacy target or to evaluate the cumulative fraction of response for any dosing regimen in this population.

17 January 2019 in Clinical Pharmacokinetics
Verified
Journal Article
Open access
PDF file
PCPieter J. Colin
Pieter J. Colin
Karel AllegaertKarel Allegaert
Karel Allegaert
ATAlison H. Thomson
Alison H. Thomson
Daniel Johannes TouwDaniel Johannes Touw
Daniel Johannes Touw
MDMichael Dolton
Michael Dolton
DEDouglas J. Eleveld
Douglas J. Eleveld
Uncertainty exists regarding the optimal dosing regimen for vancomycin in different patient populations, leading to a plethora of subgroup-specific pharmacokinetic models and derived dosing regimens. We aimed to investigate whether a single model for vancomycin could be developed based on a broad dataset covering the extremes of patient characteristics. Furthermore, as a benchmark for current dosing recommendations, we evaluated and optimised the expected vancomycin exposure throughout life and for specific patient subgroups.

16 June 2004 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
José M LanaoJosé M Lanao
José M Lanao
MCMaria Victoria Calvo
Maria Victoria Calvo
JMJosé Antonio Mesa
José Antonio Mesa
AMAna Martín-Suárez
Ana Martín-Suárez
MCMaria Teresa Carbajosa
Maria Teresa Carbajosa
ADAlfonso Domínguez-Gil
Alfonso Domínguez-Gil
Objectives: To analyse the pharmacokinetic basis for the use of extended-interval dosage regimens of gentamicin in neonates using population pharmacokinetics. Patients and methods: The population pharmacokinetics of gentamicin was studied retrospectively in a population of 113 neonates divided into two groups: one for computing the population model (n=97) and another for validation (n=36). A one-compartment pharmacokinetic model and non-linear mixed-effects modelling were used to assess the population pharmacokinetic model. Results: Weight (W) and postnatal age (PA) were the covariates that influenced the pharmacokinetic parameters of gentamicin. The final population model obtained was: distribution volume, V (L)=0.636 × W (kg)0.852; clearance, Cl (L/h)=0.032 × W (kg)1.482+0.0024 × PA (days). The predictive performance of the model in the population validation was adequate for clinical purposes. The optimized population model allowed us to simulate gentamicin serum levels and their variability, in this kind of patient, when extended-interval dosage administration regimens were implemented. Conclusions: According to our pharmacokinetic population model, initial doses of gentamicin of 10 mg/kg, and dosage intervals between 36–48 h, appear to be appropriate to achieve target peak and trough serum levels of 15–20 and <0.5 mg/L, respectively, when extended-interval dosage regimens are implemented in newborns. The half-life of gentamicin in premature babies of very low weight and gestational age <31 weeks is long. Thus, to achieve serum concentrations in the 1–10 mg/L range, the use of dosage regimens of 5 mg/kg at 36–48 h dosage intervals seems suitable.

5 February 2020 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JSJose German Sanchez-Hernandez
Jose German Sanchez-Hernandez
NRNoemí Rebollo
Noemí Rebollo
AMAna Martin‐Suarez
Ana Martin‐Suarez
MCMaria Victoria Calvo
Maria Victoria Calvo
FMFernando Muñoz
Fernando Muñoz

1 January 1989 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
MCM. V. Calvo
M. V. Calvo
AMA. Martin-Suarez
A. Martin-Suarez
CLC Martin Luengo
C Martin Luengo
CAC. Avila
C. Avila
MCM. Cascon
M. Cascon
AHA. Domfnguez-Gil Hurlé
A. Domfnguez-Gil Hurlé
The pharmacokinetic and pharmacodynamic interactions between digoxin and propafenone were investigated in 10 hospitalized patients with heart disease and cardiac arrhythmias. During steady state (0.25 mg/day) the glycoside was combined with 600 mg of propafenone daily for 1 week. The mean \pm SD serum digoxin concentration (SDC) was 0.97 \pm 0.29 ng/ml before and 1.54 \pm 0.65 ng/ml (p < 0.003) during propafenone administration. Propafenone induced a mean decrease in 31.1 and 31.7% in total and renal digoxin clearances, respectively. The increase in SDCs was accompanied by a decrease in heart rate (HR) and shortening of QTc (QT interval corrected for HR). In patients receiving digoxin and propafenone simultaneously, the SDCs should be monitored and the digoxin dose reduced if there is evidence of toxicity.

28 February 2011 in Clinical Biochemistry
Verified
Journal Article
Closed access
NRNoemí Rebollo
Noemí Rebollo
MCM. Victoria Calvo
M. Victoria Calvo
AMAna Martín-Suárez
Ana Martín-Suárez
ADAlfonso Domínguez-Gil
Alfonso Domínguez-Gil